hotspot -WSS

hotspot

author：fashion 2025-09-30 00:48:40 - browse：11467

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： With Wegovy coverage, Medicare patients may face high costs

WSS

Readout Newsletter: Illumina, CRISPR, Regeneron

Childbirth

First Opinion Podcast: What happens when kids become caregivers?

Average age of first period drops to 11.9 years, study shows

Insmed lung disease drug hits target in key Phase 3 trial

With Wegovy coverage, Medicare patients may face high costs

focus

hotspot

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Diabetes management: Digital health tools fall short, study says

In Memoriam: Notable people who died in 2023

Yancopoulos of Regeneron works to expand Dupixent success

Medical leaders decry Supreme Court decision on affirmative action

Mirador, a new biotech startup, launches with $400 million

BioMarin wins approval for gene therapy to treat hemophilia A

Yancopoulos of Regeneron works to expand Dupixent success

At least 13 dead in Texas as scorching temps continue

Childbirth

entertainment

Asbestos ban is immediate, but health effects will linger for decades

Texas board proposes rules on abortion law emergency exemption

AI used to predict Covid

This gene therapy has record $4.25 million price. It's saved children.

Adam's Take: Intra

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

knowledge

Wikipedia

hotspot

explore